Non-small cell lung cancer third-generation target
Unmet medical needs
EGFR-mutant derived non-small cell lung cancer patients account for 10-15% of all non-small cell lung cancer patients in Europe and 30-40% in Asia. These patients exhibited EGFR mutations at the time of diagnosis and progressed to T790 mutations in two of three patients with non-small cell lung cancer progressing after EGFR-TKI treatment. For patients with these mutations, therapies are currently limited.
Therefore, the development of a third-generation EGFR drug that can treat the T790M mutation is urgently required. Expansion to 1st therapy for the patients of EGFR-mutant non-small cell lung cancer.
· Patients resistant to existing EGFR inhibitor drugs, Iressa and Tarceva.
· 1st line treatment of EGFR
Lead IND enabling candidate was transferred to Yuhan. And in the middle of phase ½ clinical trial, Yuhan Licensed it out to Janssen at $1.255 Bil. In 2018. Phase 3 clinical trial for 1st line Mono commenced in Jan.,2020, and Phase 3 for combo therapy with Janssen`s bispecific antibody (JNJ-372) is to be started in 2H 2020.
Osimertinib (AstraZeneca), Olmutinib (Hanmi)
GNS-1480 has excellent drug efficacy against dual mutant non-small cell lung cancer resistant to the existing EGFR inhibitor drugs, iressa and tarceva. Because of its high blood-brain barrier permeability GNS-1480 is a potential candidate expected to have excellent effects for patients with brain metastatic non-small-cell lung cancer who do not have an effective treatment even at a high incidence rate.